Unfortunately, only a minority of HPV-negative HNSCC harbor either a PIK3CA or HRAS mutation, and therefore only a small patient group might benefit from a therapy regimen targeting these mutations [3]. The gene discussed is HRAS; the disease is head and neck squamous cell carcinoma.